Table 3.

Subgroup analysis of the association between 28-day mortality and LAR.

	No. of patients	Lactate dehydrogenase to albumin ratio			p for interaction
		T1	T2	T3
		LAR < 8.59	8.59 ≤ LAR <14.66	LAR ≥ 14.66
Sex					0.381
Male	3745	1 (Ref)	1.45 (1.21–1.74)	2.21 (1.85–2.64)
Female	2708	1 (Ref)	1.23 (1–1.52)	1.76 (1.44–2.15)
Age					0.078
<60	3118	1 (Ref)	1.30 (1–1.68)	1.55 (1.21–1.98)
≥60	3335	1 (Ref)	1.37 (1.17–1.61)	2.24 (1.91–2.62)
APS III					0.232
<42	1001	1 (Ref)	1.64 (0.93–2.88)	2.63 (1.47–4.69)
≥42	5452	1 (Ref)	1.3 (1.13–1.49)	1.87 (1.64–2.15)
RRT					0.299
Yes	238	1 (Ref)	1.12 (0.46–2.7)	1.23 (0.58–2.59)
No	6215	1 (Ref)	1.36 (1.19–1.56)	2.02 (1.76–2.31)
Vasopressor use					0.465
Yes	790	1 (Ref)	1.19 (0.79–1.78)	2.00 (1.37–2.92)
No	5663	1 (Ref)	1.38 (1.2–1.6)	1.98 (1.72–2.28)
Loop diuretics use					0.099
Yes	691	1 (Ref)	2 (1.33–3)	2.11 (1.41–3.16)
No	5762	1 (Ref)	1.3 (1.12–1.5)	2 (1.74–2.3)
Myocardial infarct					0.017
Yes	1256	1 (Ref)	1.66 (1.18–2.35)	3.13 (2.26–4.33)
No	5197	1 (Ref)	1.31 (1.13–1.52)	1.82 (1.57–2.11)
Congestive heart failure					0.686
Yes	2240	1 (Ref)	1.36 (1.09–1.69)	2.18 (1.75–2.7)
No	4213	1 (Ref)	1.42 (1.19–1.68)	2.01 (1.7–2.38)
Malignant cancer					0.436
Yes	997	1 (Ref)	1.49 (1.08–2.04)	2.67 (1.96–3.63)
No	5456	1 (Ref)	1.32 (1.13–1.53)	1.87 (1.61–2.16)
Septic shock					0.439
Yes	832	1 (Ref)	1.31 (0.95–1.81)	1.83 (1.35–2.49)
No	5621	1 (Ref)	1.37 (1.18–1.59)	2.03 (1.75–2.34)
AKI stage					0.090
1	1058	1 (Ref)	1.78 (1.19–2.66)	2.08 (1.36–3.18)
2	2895	1 (Ref)	1.31 (1.04–1.65)	2.25 (1.79–2.83)
3	2500	1 (Ref)	1.32 (1.09–1.59)	1.71 (1.44–2.04)
Liver disease
Yes	1598	1 (Ref)	1.33 (1.04–1.69)	1.47 (1.16–1.86)	<0.001
No	4855	1 (Ref)	1.37 (1.16–1.61)	2.37 (2.02–2.78)

HRs (95% CIs) were derived from Cox proportional hazards regression models. Each stratification was adjusted for all factors included in Model 3 in Table 2 except the stratification factor itself. APS III, acute physiology score; RRT, renal replacement treatment; AKI, acute kidney injury.